Ignite Creation Date:
2024-05-06 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04686487
Status:
COMPLETED
Last Update Posted:
2022-11-30
First Post:
2020-12-15
Brief Title:
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
Sponsor:
Second Xiangya Hospital of Central South University
Organization:
Second Xiangya Hospital of Central South University
Study Overview
Official Title:
Stereotactic Ablative Radiotherapy in Patients With Hypertrophic Obstructive Cardiomyopathy First in Man Pilot Study
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SELECT
Brief Summary:
Hypertrophic obstructive cardiomyopathy HOCM is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiting the heart with increasing risk of sudden cardiac death heart failure and atrial fibrillation Surgical septal myectomy and alcohol septal ablation are two invasive therapies for drug-refractory symptomatic patients with HOCM Unfortunately some patients may be unsuitable for both the two procedures Recently stereotactic ablative radiotherapy usually used for the treatment of tumours was confirmed to be feasible safe and effective in destroying abnormal tissue in heart by targeting high energy heavy ion beams at a specific area of the body precisely In this study we will determine whether radiation ablation can be used to destroy the thick heart muscle at the point of obstruction safely and effectively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None